Introduction {#s01}
============

*Mycobacterium tuberculosis* (*Mtb*), the etiologic agent of tuberculosis (TB), causes up to 8.8 million new clinical infections and 1.4 million deaths annually ([@bib23]). In the mouse model of TB, the acute phase of infection is marked by exponential growth of the bacteria in the lungs. In its persistence phase, *Mtb* undergoes a metabolic shift, triggered by changes in nutrient availability as substrates for glycolysis become limited ([@bib1]). The bacterial glyoxylate shunt pathway is an alternative anaplerotic pathway that facilitates the use of fatty acids as a carbon source for biosynthetic pathways and generation of ATP. *Mtb* strains encode at least one and sometimes two isocitrate lyases (ICL1 and ICL2) that function within the glyoxylate shunt ([@bib9]; [@bib6]). Mutation of the ICL genes has provided evidence for a role of the glyoxylate shunt in *Mtb* pathogenesis ([@bib16]; [@bib18]).

The host Immune-Responsive Gene 1 (Irg1; also called *Acod1*) is a mitochondrial enzyme induced under inflammatory conditions that produces the metabolite itaconate by decarboxylating cis-aconitate, a TCA cycle intermediate ([@bib17]). Because itaconate production in myeloid cells reportedly inhibits bacterial ICLs, it has gained interest as an endogenous antibacterial effector molecule ([@bib15]). This role was supported by a study showing that nonphysiologically relevant (25 mM) concentrations of itaconate had bacteriostatic effects on *Mtb* growth during liquid culture under conditions requiring the glyoxylate shunt pathway ([@bib17]).

Beyond its possible antibacterial functions, itaconate also links immune cell metabolism and inflammatory responses. Irg1 is highly expressed in macrophages in response to proinflammatory stimuli that induce type I and type II IFN signaling ([@bib5]). In bone marrow--derived macrophages (BMDMs), itaconate suppressed the production of mitochondrial ROS as well as proinflammatory cytokines, including IL1-β, IL6, and IL12p70 ([@bib13]). This capacity to modulate inflammation could be of particular importance during *Mtb* infection because excessive immune responses can prevent bacterial clearance and cause pathology ([@bib20]; [@bib12]).

We addressed the function of Irg1 in regulating immune responses and *Mtb* pathogenesis using *Irg1^−/−^* and *Irg1*^fl/fl^ conditional gene-deleted mice. A complete absence of Irg1 during *Mtb* infection resulted in severe pulmonary disease and ultimately death, with greater numbers of infected myeloid cells and higher production of inflammatory cytokines and chemokines. Irg1 expression in myeloid cell subsets was necessary to control neutrophil recruitment, *Mtb* infection, and immune-mediated tissue injury. Our studies define a key role for Irg1 in regulating immune cell metabolism in subsets of myeloid cells, which minimizes the pathological immune response that contributes to pulmonary disease caused by *Mtb*.

Results and discussion {#s02}
======================

To determine the role of Irg1 during *Mtb* infection, *Irg1^−/−^* C57BL/6N mice were monitored for clinical and bacterial outcomes after aerosol inoculation with the *Mtb* Erdman strain. Whereas all WT mice survived past 80 d postinfection (dpi), ∼75% of *Irg1^−/−^* mice succumbed to *Mtb* within 30 d, a phenotype similar to animals lacking IFN-γ signaling ([Fig. 1 A](#fig1){ref-type="fig"}; [@bib4]; [@bib7]; [@bib20]). At 21 dpi, the lungs of *Irg1^−/−^* mice infected with *Mtb* had larger numbers and sizes of macroscopic lesions compared with infected WT mice ([Fig. 1 B](#fig1){ref-type="fig"}). Although bacterial levels were similar in the lungs and spleens of WT and *Irg1*^−/−^ mice at 10 dpi, by 14 and 21 dpi, the *Mtb* burden was ∼3- and 25-fold higher, respectively, in the lungs of *Irg1^−/−^* compared with WT mice (P \< 0.01; [Fig. 1 C](#fig1){ref-type="fig"}, left). At 21 dpi, *Mtb* burden also was approximately eightfold higher in the spleens of *Irg1^−/−^* compared with WT mice ([Fig. 1 C](#fig1){ref-type="fig"}, right). We also tested the effects of Irg1 on *Listeria monocytogenes* (strain EGD), an intracellular bacterium administered by intravenous injection, and Influenza A virus (IAV strain A/California/04/2009 H1N1), a respiratory pathogen inoculated by intranasal route ([Fig. 1, D--F](#fig1){ref-type="fig"}). Loss of Irg1 expression in mice did not result in altered susceptibility to *Listeria monocytogenes* ([Fig. 1 D](#fig1){ref-type="fig"}) or IAV infection ([Fig. 1, E and F](#fig1){ref-type="fig"}).

![**Irg1 is essential for host resistance to *Mtb*. (A--C)** WT and *Irg1*^−/−^ mice were infected with aerosolized *Mtb*. **(A)** Survival analysis. **(B)** Gross pathology of lungs at day 21. **(C)** *Mtb* burden (GFP^+^ Erdman strain) was measured at days 10 (*n* = 6), 14 (*n* = 10), and 21 (*n* = 11--12) after infection. **(D)** WT and *Irg1*^−/−^ mice were inoculated intravenously with *Listeria monocytogenes* (LM) and monitored for survival (*n* = 12--13). **(E and F)** WT and *Irg1^−/−^* mice were infected intranasally with IAV and monitored for survival and weight loss (E), and lung viral burden at 5 dpi (F; *n* = 9--10). **(A--F)** All data are from at least two independent experiments. Statistical differences are indicated**. (C, E \[right\]**, **and F)** Mann-Whitney test: \*, P \< 0.05; \*\*\*\*, P \< 0.0001; ns, not significant. **(A, D, and E \[left\])** Log-rank test. ns, not significant. Error bars designate SEM.](JEM_20180118_Fig1){#fig1}

The strain of *Mtb* used in this study, Erdman, encodes two ICL genes, *ICL1* and *ICL2*. In vivo, *Δicl1 Mtb* strains replicate normally during the acute phase, but are attenuated during the chronic, persistent phase of infection, whereas *Δicl2 Mtb* strains show no defects in infection ([@bib16]; [@bib18]). *Δicl1 Δicl2* strains are avirulent in vivo, possibly because ICL has additional methylisocitrate lyase activity that prevents toxic accumulation of propionyl-CoA ([@bib18]; [@bib19]; [@bib21]). To test the impact of Irg1 on the bacterial glyoxylate shunt in vivo, we infected WT and *Irg1*^−/−^ mice with WT and isogenic *Δicl1 Mtb* strains. As anticipated, 100% of WT mice infected with WT or *Δicl1 Mtb* survived infection over an 80-d time course (Fig. S1 A). In contrast, all *Irg1*^−/−^ mice infected with *Δicl1 Mtb* succumbed to infection without differences in mean time to death (Fig. S1 A) or relative weight loss (Fig. S1 B) compared with the isogenic WT *Mtb* strain. Moreover, *Δicl1* bacterial titers in the lung and the spleen of *Irg1^−/−^* mice were ∼83- and ∼12-fold higher than in WT mice, respectively (Fig. S1 C). Because *Δicl1 Mtb* lacks a fully functional glyoxylate shunt pathway, yet is still virulent in *Irg1*^−/−^ mice, Irg1 likely restricts *Mtb* infection in vivo independently of its activity on ICL1.

We next evaluated whether Irg1-dependent regulation of inflammatory responses ([@bib13]) contributed to *Mtb* pathogenesis. We infected WT and *Irg1*^−/−^ mice with an *Mtb* strain expressing GFP (*Mtb*-GFP) that has the same virulence properties as WT *Mtb* (Fig. S1 F). Histological analysis at 21 dpi showed that lung lesions from *Mtb*-GFP--infected *Irg1*^−/−^ mice were larger in size with denser cellular infiltrates ([Fig. 2 A](#fig2){ref-type="fig"}). To define the composition of these infiltrates, we profiled immune cells in *Mtb*-GFP--infected lungs by flow cytometry (gating strategy defined in Fig. S2 A). At 10 dpi, no differences in the number of neutrophils, inflammatory monocytes, infiltrating macrophages, alveolar macrophages, dendritic cells, natural killer (NK) and NKT cells, or eosinophils were detected in the lungs of WT and *Irg1*^−/−^ mice ([Fig. 2, B and C](#fig2){ref-type="fig"}). However, by day 14, infected lungs from *Irg1*^−/−^ mice had greater numbers of neutrophils (approximately fourfold) and eosinophils (threefold) than WT mice, and this difference remained at day 21 for neutrophils ([Fig. 2, B, D, and E](#fig2){ref-type="fig"}). At 21 dpi, lungs from *Irg1*^−/−^ mice also had lower numbers of alveolar macrophages (1.3-fold) and NK1.1^+^ cells (approximately threefold). Analysis of other innate immune cell populations in the lungs at 14 and 21 dpi revealed no significant differences in numbers of inflammatory monocytes, infiltrating macrophages, and infiltrating and resident dendritic cells between *Mtb*-GFP--infected WT and *Irg1*^−/−^ mice. In addition, no differences in the numbers of CD4^+^ T cells, CD8^+^ T cells, and B cells were found between WT and *Irg1^−/−^* mice at 21 dpi (Fig. S2 B).

![**Irg1 modulates inflammatory responses in the lung after *Mtb* infection.** Mice were infected with aerosolized *Mtb*-GFP. **(A)** Histopathology was visualized by H&E staining of lungs at 21 dpi. Images are representative of two independent experiments. Bars: 2.5 mm (1.25×); 50 µm (40×). **(B)** Flow cytometry plots for neutrophils as a percentage of total CD45^+^ cells in lungs before *Mtb* infection and at 10, 14, and 21 dpi. Data are representative of results from *n* = 6--15 mice depending on the time point. **(C--E)** Number of innate immune cell populations in lungs at 10 dpi (C; *n* = 6), 14 dpi (D; *n* = 10), and 21 dpi (E; *n* = 6--15). **(F--H)** Cytokine and chemokine levels in the *Mtb*-infected lungs at 10 dpi (F; *n* = 6), 14 dpi (G; *n* = 10), and 21 dpi (H; *n* = 6). **(I)** Acid-fast bacilli in *Mtb*-infected lungs at 21 dpi. Images are representative of two independent experiments. Bars, 10 µm. **(J)** Flow cytometry plots for *Mtb*-GFP^+^ neutrophils in lungs at 10, 14, and 21 dpi. SSC, side scatter. **(K)** The percentage of *Mtb*-GFP-positive cells in indicated cell types at 10 (*n* = 6), 14 (*n* = 8--10), and 21 (*n* = 6--15) dpi. All data are pooled from at least two independent experiments. (**C--H and K**) Bars indicate median values. Statistical differences were determined by Mann-Whitney test (\*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001; ns, not significant). Mφ, macrophages. See also Figs. S1 and S2.](JEM_20180118_Fig2){#fig2}

We measured the effect of Irg1 on the accumulation of inflammatory mediators in the lung during *Mtb*-GFP infection. Equivalent levels of chemokines and proinflammatory cytokines in lung homogenates of WT and *Irg1*^−/−^ mice were detected at 10 dpi ([Fig. 2 F](#fig2){ref-type="fig"} and Fig. S2 C). By 14 dpi, higher levels of several proinflammatory cytokines (IL1-β, IL6, IL17, and G-CSF) and chemokines (CXCL1, CCL3, and CCL4) were detected in the lungs of *Irg1*^−/−^ mice compared with WT mice ([Fig. 2 G](#fig2){ref-type="fig"}), although TNF-α levels remained unchanged (Fig. S2 C). By 21 dpi, all proinflammatory cytokines (IL1-β, IL6, IL12p70, IL17, IFN-γ, TNF-α, and G-CSF) and chemokines (CCL2, CXCL1, CCL3, and CCL4) measured were higher in the lungs of *Irg1*^−/−^ mice compared with WT mice ([Fig. 2 H](#fig2){ref-type="fig"} and Fig S2 C).

Because *Irg1^−/−^* mice infected with WT or *Δicl1 Mtb* succumbed to infection at equivalent rates (Fig. S1 A), we investigated if the inflammatory responses in these mice was similar. *Δicl1 Mtb*--infected *Irg1*^−/−^ mice also showed increased accumulation of neutrophils in their lungs at 21 dpi (Fig. S1 D). Correspondingly, proinflammatory cytokines (IL1-β, IL6, IL12p70, IL17, G-CSF, and IFN-γ) and chemokines (CCL2, CCL3, CCL4, and CXCL1) were higher in *Δicl1 Mtb*­--infected *Irg1*^−/−^ mice compared with WT mice (Fig. S1 E). The similar levels of increased neutrophil accumulation in response to both WT and *Δicl1 Mtb* in *Irg1*^−/−^ mice supports the hypothesis that the defect in controlling *Mtb* infection in these mice is independent of ICL1 activity and a fully functional glyoxylate shunt pathway.

We evaluated whether accumulating myeloid cells in the lung were infected with *Mtb*. At 21 dpi, lung lesions were the preferred sites for *Mtb* infection, with greater numbers of acid-fast bacilli present in *Irg1*^−/−^ mice ([Fig. 2 I](#fig2){ref-type="fig"}). To analyze infection in each myeloid cell type, we monitored the presence of *Mtb*-GFP by flow cytometry. At 10 and 14 dpi, each myeloid cell type in WT and *Irg1^−/−^* lungs was infected at similar frequencies ([Fig. 2, J and K](#fig2){ref-type="fig"}). By 21 dpi, lungs from *Irg1*^−/−^ mice had higher percentages of infected neutrophils (eightfold), inflammatory monocytes (19-fold), infiltrating macrophages (19-fold), and CD11b^+^ dendritic cells (approximately threefold) compared with WT mice ([Fig. 2, J and K](#fig2){ref-type="fig"}). Collectively, this data suggests that Irg1 regulates inflammatory responses, which controls the recruitment of multiple types of myeloid cells, many of which become targets for subsequent rounds of *Mtb* infection. Irg1 did not have a direct effect on *Mtb* infectivity in cell culture, as no differences in bacterial titers were detected in WT and *Irg1^−/−^* BMDMs (Fig. S1 G).

In macrophage-lineage cells from zebrafish, Irg1 was suggested to promote antibacterial effects by regulating the use of fatty acids, which are substrates for mitochondrial ROS (mROS) production ([@bib8]). To determine whether *Irg1^−/−^* mice had less mROS expression in key myeloid cells as an explanation for the failure to control *Mtb* infection, we evaluated mROS levels in neutrophils in vivo at 21 dpi. However, neutrophils from *Mtb*-infected *Irg1^−/−^* mice had a higher expression of mROS (Fig. S2 D). Exogenous itaconate treatment of activated BMDMs in vitro also was shown to suppress mROS and inducible nitric oxide synthase (iNOS) expression ([@bib13]). Consistent with these findings, *Irg1^−/−^* mice had a higher frequency and number of iNOS-producing neutrophils (Fig. S2 D). Thus, the higher production of mROS and iNOS in *Irg1^−/−^* neutrophils suggests these cells are in a hyperinflamed state, rather than being defective in these antimicrobial mediators.

To begin to define which cell types required Irg1 expression to control *Mtb* infection, we established reciprocal bone marrow chimeric mice by replacing the WT and *Irg1*^−/−^ recipient marrow with the donor marrow cells from *Irg1*^−/−^ and WT mice or using WT marrow into donor WT mice as controls (Fig. S3 A). Whereas WT → WT and WT → *Irg1^−/−^* mice survived *Mtb* infection for over 80 dpi, *Irg1^−/−^*→ WT mice succumbed to *Mtb* infection by 32 dpi, demonstrating that the protective response was derived from Irg1-sufficient radiosensitive cells (Fig. S3 B). *Mtb* titers in the lungs and the spleen of *Irg1^−/−^* → WT mice were higher than WT → WT mice at 21 dpi (∼10-fold and threefold, respectively; Fig. S3 C). At 21 dpi *Irg1^−/−^*→ WT mice had greater accumulation of neutrophils in their lungs than WT → WT mice (Fig. S3 D), whereas no differences in recruitment of other innate immune populations were seen.

Excessive neutrophil recruitment is associated with progression of *Mtb* disease ([@bib20]; [@bib12]). To test whether the susceptibility of the *Irg1^−/−^* mice to *Mtb* infection was a result of the increased accumulation of neutrophils in the lung, we administered a neutrophil-depleting (anti-Ly6G) or isotype control antibody to WT and *Irg1*^−/−^ mice, beginning on day 10 with repeated injections every other day through day 34. Treatment of *Irg1*^−/−^ mice from day 10 to 34 with anti-Ly6G prolonged survival during *Mtb* infection ([Fig. 3 A](#fig3){ref-type="fig"}). Depletion of neutrophils starting at day 10 also resulted in reduced *Mtb* burden in the lungs at 21 dpi (19-fold) compared with isotype control--treated *Irg1*^−/−^ mice. However, the levels of *Mtb* in neutrophil-depleted *Irg1^−/−^* mice still were higher (ninefold) than in antibody-treated WT mice ([Fig. 3 B](#fig3){ref-type="fig"}), indicating that recruitment and infection of neutrophils partially contributed to the higher bacterial burden in *Mtb*-infected *Irg1^−/−^* mice. Correspondingly, diminished numbers of bacilli were present in lung sections of *Irg1*^−/−^ mice treated with anti-Ly6G mAb compared with the isotype control ([Fig. 3 C](#fig3){ref-type="fig"}). Lung lesions from *Mtb*-infected, anti-Ly6G mAb-treated *Irg1*^−/−^ mice were smaller than isotype-treated counterparts ([Fig. 3 C](#fig3){ref-type="fig"}). Cytokine and chemokine levels in the lung also were decreased in neutrophil-depleted *Irg1*^−/−^ mice at 21 dpi ([Fig. 3 D](#fig3){ref-type="fig"}). At 21 dpi, as expected, anti-Ly6G mAb treatment of *Irg1^−/−^* mice had reduced the number of neutrophils compared with isotype control--treated animals ([Fig. 3 E](#fig3){ref-type="fig"} and Fig. S2 E). With the exception of a small decrease in numbers of inflammatory monocytes, the recruitment of which could be altered by decreases in lung cytokine and chemokine expression as a result of neutrophil depletion, all other innate immune cell subsets were unaffected by neutrophil depletion ([Fig. 3 E](#fig3){ref-type="fig"}). Once the neutrophil depletion treatment was stopped and neutrophils were allowed to accumulate in the lung, disease ensued and all *Irg1^−/−^* mice succumbed to infection. Thus, depletion of neutrophils mitigates the bacterial and proinflammatory pathological phenotypes observed at day 21 after infection in *Irg1*^−/−^ mice, and a dysfunctional neutrophil response contributes to the susceptibility of these mice to *Mtb* infection.

![**Depletion of neutrophils enhances survival of *Mtb*-infected *Irg1^−/−^* mice.** WT and *Irg1*^−/−^ mice were infected with aerosolized *Mtb* and treated with anti-Ly6G or isotype control antibodies as described in the Materials and methods. **(A)** Survival analysis (*n* = 7--8). **(B)** *Mtb* burden in the lung at 21 dpi (*n* = 7--8). Lines indicate median values. **(C)** Lung histopathology and acid-fast bacilli at 21 dpi were visualized with H&E (top) and acid-fast (bottom) stains. Images are representative of two independent experiments. Bars: 1 mm (top); 100 µm (bottom). **(D)** Cytokine levels at 21 dpi (*n* = 6). **(E)** Innate immune cell populations in the lung at 21 dpi (*n* = 6). All data are pooled from two independent experiments. Statistical differences were determined via one-way ANOVA with Tukey's correction (B and D) and Mann-Whitney test (E; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001; ns, not significant). See also Fig. S2.](JEM_20180118_Fig3){#fig3}

We next sought to identify the cell types that expressed Irg1 and modulated neutrophil accumulation and *Mtb* disease pathogenesis. Because Irg1 is expressed principally in cells of myeloid lineage ([@bib5]; [@bib8]; [@bib17]; [@bib13]), we tested its role in *Mtb* infection in different myeloid cell subsets using mice lacking Irg1 expression in neutrophils (*Mrp8*-Cre^+^ *Irg1*^fl/fl^), alveolar macrophages and some dendritic cells (*CD11c*-Cre^+^ *Irg1*^fl/fl^), or monocytes/macrophages, alveolar macrophages, neutrophils, and some dendritic cells (*LysM*-Cre^+^ *Irg1*^fl/fl^; Fig. S3, E--G). Although all Cre^−^*Irg1*^fl/fl^ and *Mrp8*-Cre^+^ *Irg1*^fl/fl^ mice survived past 150 dpi, all *LysM*-Cre*^+^ Irg1*^fl/fl^ mice succumbed to *Mtb* within 40 dpi, a phenotype similar to *Irg1^−/−^* mice ([Fig. 4 A](#fig4){ref-type="fig"}). In comparison, all *CD11c*-Cre^+^ *Irg1*^fl/fl^ mice succumbed to *Mtb* by 135 dpi. Consistent with these survival results, *Mtb* levels in the lungs of *Mrp8*-Cre^+^ *Irg1*^fl/fl^ mice were similar to littermate Cre^−^ *Irg1*^fl/fl^ controls, whereas *CD11c*-Cre^+^ *Irg1*^fl/fl^ and *LysM*-Cre*^+^ Irg1*^fl/fl^ mice both had greater pulmonary bacterial burden at 21 dpi (∼3.5-fold and 14-fold, respectively; [Fig. 4 B](#fig4){ref-type="fig"}). At 21 dpi, both *LysM*-Cre*^+^ Irg1*^fl/fl^ and *CD11c*-Cre^+^ *Irg1*^fl/fl^ mice had greater numbers of neutrophils in their lungs than *Cre*^−^ *Irg1*^fl/fl^ mice ([Fig. 4, C--E](#fig4){ref-type="fig"}), but *Mrp8*-Cre^+^ *Irg1*^fl/fl^ mice did not ([Fig. 4 F](#fig4){ref-type="fig"}). Loss of Irg1 expression in myeloid cells (*LysM*-Cre*^+^ Irg1*^fl/fl^ mice) resulted in higher levels of cytokines and chemokines in the lungs at 21 dpi ([Fig. 4 G](#fig4){ref-type="fig"}). Loss of Irg1 expression in alveolar macrophages and some dendritic cell subsets from *CD11c*-Cre^+^ *Irg1*^fl/fl^ mice also resulted in greater amounts of inflammatory cytokines and chemokines. In comparison, deletion of Irg1 in neutrophils had little effect on cytokine responses. These data show that Irg1 expression in CD11c^+^ and LysM^+^ cell subsets regulates neutrophil recruitment and inflammation. Although neutrophils mediate *Mtb*-induced immunopathology in *Irg1*^−/−^ mice, their cell-intrinsic expression of Irg1 is dispensable for this process.

![**Loss of *Irg1* in myeloid cell subsets confers susceptibility to *Mtb*.** Mice were infected with aerosolized *Mtb*. **(A)** Survival analysis of Cre^−^ *Irg1*^fl/fl^, *Mrp8*-Cre^+^ *Irg1*^fl/fl^, *CD11c*-Cre^+^ *Irg1*^fl/fl^, and *LysM*-Cre^+^ *Irg1*^fl/fl^ mice (*n* = 6--23) after *Mtb* infection. **(B)** *Mtb* burden in lungs of Cre^−^ *Irg1*^fl/fl^ (*n* = 15), *Mrp8*-Cre*^+^ Irg1*^fl/fl^ (*n* = 5), *CD11c*-Cre^+^ *Irg1*^fl/fl^ (*n* = 9), and *LysM*-Cre^+^ *Irg1*^fl/fl^ (*n* = 9) mice at 21 dpi. Lines indicate median values. **(C)** Flow cytometry plots of lung neutrophils (P1), inflammatory monocytes (P2), and infiltrating macrophages (P3) as a percentage of the total CD45^+^ CD11c^−^CD11b^+^ population in *Cre*^−^ *Irg1*^fl/fl^, *LysM*-Cre^+^ *Irg1*^fl/fl^, and *CD11c*-Cre^+^ *Irg1*^fl/fl^ mice at 21 dpi. **(D--F)** Quantitation of myeloid cells in lungs of *Cre*^−^ *Irg1*^fl/fl^ (*n* = 6) and *LysM*-Cre^+^ *Irg1*^fl/fl^ (D; *n* = 9), *Cre*^−^ *Irg1*^fl/fl^ (*n* = 5) and *CD11c*-Cre^+^ *Irg1*^fl/fl^ (E; *n* = 9), and *Cre*^−^ *Irg1*^fl/fl^ (*n* = 4) and *Mrp8*-Cre^+^ *Irg1*^fl/fl^ (F; *n* = 5) mice at 21 dpi. Mφ, macrophages. **(G)** Cytokine levels at 21 dpi (*n* = 5--14). All data are pooled from at least two independent experiments. Bars indicate median values. Statistical differences were determined via log-rank test with a Bonferroni post-hoc correction for multiple comparisons (A; \*\*\*\*, P \< 0.0001) and Mann-Whitney test (B and D--G; \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001; ns, not-significant). See also Fig. S3.](JEM_20180118_Fig4){#fig4}

To gain insight into why a lack of Irg1 expression in myeloid cells resulted in excessive accumulation of neutrophils in *Irg1*^−/−^ mice during *Mtb* infection, we compared the expression profiles of *Mtb*-infected WT and *Irg1^−/−^* BMDMs. Within just 4 h of *Mtb* infection, the transcriptional signature in *Irg1*^−/−^ BMDMs differed markedly from WT BMDMs. Many of the genes that were up-regulated in *Irg1*^−/−^ cells after *Mtb* infection were down-regulated in WT BMDMs ([Fig. 5 A](#fig5){ref-type="fig"}). Exogenous addition of physiologically relevant doses of itaconate (0.25 mM; [@bib17]; [@bib13]) to *Mtb*-infected *Irg1*^−/−^ BMDMs switched the transcriptional signature to one similar to *Mtb*-infected WT BMDMs ([Fig. 5 A](#fig5){ref-type="fig"}). This result suggests that the effect of *Irg1* deletion on transcriptional profiles was principally a result of the loss of itaconate production. Pathway enrichment analysis indicated that a lack of Irg1 expression in *Mtb*-infected BMDMs resulted in induction of inflammatory and chemoattractant genes downstream of NF-κB signaling, and correspondingly, addition of itaconate to *Irg1^−/−^* BMDMs reverses this effect ([Fig. 5, B and C](#fig5){ref-type="fig"}). These data show that Irg1 and its product itaconate function to limit inflammation during *Mtb* infection at the transcriptional level.

![**Irg1 alters the transcriptional signature in *Mtb*-infected BMDMs. (A--C)** Transcriptomic data from WT, *Irg1^−/−^*, and *Irg1^−/−^* + itaconate (Ita)--treated BMDMs infected with *Mtb* and analyzed at 4 h postinfection (hpi). **(A)** Heat map comparing the transcriptional changes that occur at 4 hpi in *Irg1^−/−^* BMDMs ± Ita and WT BMDMs (left). Genes that are up-regulated in WT BMDMs also are enriched in *Irg1^−/−^* + itaconate BMDMs at 4 hpi. Columns and rows show conditions and genes, respectively. Genes are ranked according to significance of differential expression and direction of change. Plot shows the running score for NF-κB gene set as the analysis moves down the ranked list (right). **(B and C)** Gene set enrichment analysis comparison for genes in NF-κB signaling (B) and inflammatory chemokine CXCL11 and IL1-β (C) between WT versus *Irg1^−/−^*, WT versus *Irg1^−/−^ +* Ita, and *Irg1^−/−^* + Ita versus *Irg1^−/−^* BMDMs. Error bars designate SEM.](JEM_20180118_Fig5){#fig5}

How does Irg1 regulate inflammation during *Mtb* infection? Irg1 has been reported to suppress production of TLR-triggered NF-κB--dependent cytokines, including TNF-α, through induction of the negative regulator A20 ([@bib14]; [@bib10]). Although an increased inflammatory response was detected in the lungs of *Irg1^−/−^* mice at 14 dpi, we failed to detect differences in TNF-α levels compared with WT lung homogenates. Thus, in the context of *Mtb* infection Irg1 appears to modulate inflammatory responses by dampening expression of a selected subset of NF-κB regulated genes. Analogously, exogenous itaconate treatment of activated macrophages or LPS treatment of *Irg1*^−/−^ macrophages also did not affect TNF-α levels relative to their respective controls ([@bib13]).

In summary, our experiments establish an essential role of Irg1 in regulating neutrophil-dependent inflammation during *Mtb* infection of the lung. We show that Irg1, likely through its ability to convert the TCA cycle intermediate cis-aconitate to itaconate, shapes the host immune responses through an immunometabolism axis to curtail *Mtb*-induced lung disease. As mouse Irg1 is ∼80% identical in amino acid sequence to human IRG1 with all five predicted cis-aconitate decarboxylase domains fully conserved ([@bib17]), the development of pharmacological agents that enhance Irg1 function or promote itaconate production might minimize pathological inflammatory responses that cause severe lung injury associated with TB disease progression.

Materials and methods {#s03}
=====================

Ethics statement {#s04}
----------------

All procedures involving animals were conducted following the National Institutes of Health (NIH) guidelines for housing and care of laboratory animals and performed in accordance with institutional regulations after protocol review and approval by the Institutional Animal Care and Use Committee of the Washington University in St. Louis School of Medicine (protocol no. 20160118). Washington University is registered as a research facility with the United States Department of Agriculture and is fully accredited by the American Association of Accreditation of Laboratory Animal Care. The Animal Welfare Assurance is on file with Office for Protection from Research Risks--NIH. All animals used in these experiments were subjected to no or minimal discomfort. All mice were euthanized by CO~2~ asphyxiation, which is approved by the American Veterinary Association Panel on Euthanasia.

Mice {#s05}
----

C57BL/6N (WT) mice were either purchased from Charles River or bred in-house. No differences in survival or disease progression during *Mtb* infection were observed in *Irg1^+/+^* littermate controls or *Irg1*^+/+^ C57BL/6N mice obtained from Charles River in three independent experiments. B6.SJL (CD45.1) mice were obtained from Jackson Laboratories. *Irg1*^−/−^ mice (embryonic stem cells obtained from KOMP \[C57BL/6N background, reporter-tagged insertion with conditional potential, MGI: 103206\]) were generated at Washington University and have been described previously ([@bib13]). Adult mice (6--13 wk of age) of both sexes were used, and sex was randomized between experiments. Cre^−^ *Irg1*^fl/fl^ mice were generated as described previously ([@bib2]) with two loxP sites flanking exon 4 of Irg1. *Irg1^−/−^* mice were bred with *FLPe* "deleter" mice ([@bib11]) to facilitate deletion of *lacZ* and neomycin resistance cassettes between FRT sites and create *Irg1^fl/+^* founder mice. The founder mice were backcrossed to C57BL6/J background using speed congenic approaches (\>99% purity) and then interbred to generate *Irg1*^fl/fl^ mice. These animals were crossed with *Mrp8*-Cre*^+^*--, *LysM*-Cre^+^-- and *CD11c*-Cre^+^--(Jackson Laboratory) expressing mice to delete exon 4 of *Irg1* from specific subsets of myeloid cells.

Generation of bone marrow chimeric mice {#s06}
---------------------------------------

Bone marrow chimeric mice were generated by irradiation (900 Gy) of WT or *Irg1^−/−^* recipients and reconstitution with 10^7^ bone marrow cells from WT or *Irg1^−/−^* donors. 6--8 wk after bone marrow transplantation, *Irg1*^−/−^ (CD45.2) → WT (CD45.1), WT (CD45.1) → *Irg1*^−/−^ and WT (CD45.1) → WT (CD45.2), and WT (CD45.1) + *Irg1^−/−^* (CD45.2) → WT (CD45.1) mice were bled to confirm chimerism by flow cytometry before *Mtb* infection.

Mouse infections {#s07}
----------------

*Mtb* cultures in logarithmic growth phase (OD~600~ = 0.5--0.8) were washed with PBS + 0.05% Tween 80, sonicated to disperse clumps, and diluted in sterile water. Mice were exposed to 1.6 × 10^8^ CFUs of *Mtb*, a dose chosen to deliver 100--200 CFUs of aerosolized *Mtb* per lung using an inhalation exposure system (Glas-Col). For each infection, lungs were harvested from at least two control mice, homogenized, and plated on 7H11 agar to confirm the input CFU dose. The mean dose determined at this time point was assumed to be representative of the dose received by all other mice infected concurrently. *Mtb* burden was determined after homogenizing the superior, middle, and inferior lobes of the lung or the entire spleen and plating serial dilutions on 7H11 agar. Colonies were counted after 3 wk of incubation at 37°C in 5% CO~2~.

*Listeria monocytogenes* (strain EGD) was stored at mid--logarithmic growth as frozen glycerol stocks. Thawed bacteria were diluted into pyrogen-free saline for intravenous injection into mice at a dose of 10^5^ bacteria/mouse in 200 µl.

Mice were infected with IAV strain A/California/04/2009 H1N1 by intranasal inoculation of 10^5^ or 10^6^ tissue culture dose. At 5 dpi viral titer was assessed from bronchoalveolar (BAL) fluid by tissue culture dose.

Neutrophil depletions {#s08}
---------------------

Mice were administered 200 µg of anti-Ly6G mAb (1A8; BioXCell) or rat IgG2a isotype control mAb (2A3; BioXCell) diluted in sterile PBS (Hyclone) by intraperitoneal injection every 48 h, beginning at 10 dpi and ending at 20 or 34 dpi, depending on the experiment. For confirmation of depletion during survival experiments, lungs from one anti-Ly6G treated *Irg1^−/−^* control mouse and one isotype treated *Irg1^−/−^* control mouse were harvested from each independent experiment and analyzed by flow cytometry for reduction in CD45^+^/CD11b^+^Ly6C^mid^ cells.

Infection of BMDMs {#s09}
------------------

Macrophages were obtained by culturing bone marrow cells in RPMI-1640 (Invitrogen) supplemented with 10% heat-inactivated FBS, 2 mM [l]{.smallcaps}-glutamine, 1% nonessential amino acids, 100 U penicillin per ml, 100 µg streptomycin per ml, and 22 ng M-CSF (Peprotech)/ml for 6 d at 37°C, 5% CO~2~. Fresh media was added on day 3 of culture. After 6 d of culture, nonadherent cells were discarded. Adherent macrophages were switched into antibiotic-free media and seeded at 10^5^ cells per well and 9 × 10^5^ cells per well in tissue culture-treated 96- and 6-well plates, respectively. In some cases, macrophages were treated with physiologically relevant concentrations of 0.25 mM itaconic acid (Sigma) for 12 h before inoculation with *Mtb* ([@bib17]). *Mtb* was grown to midlog phase, washed with PBS, sonicated to disperse clumps, and resuspended in antibiotic-free macrophage culture media. Macrophage cultures were inoculated by adding *Mtb*-containing media at a multiplicity of infection of 1 and centrifuging for 10 min at 200 *g*. Cells were washed twice with PBS to remove unbound *Mtb*, fresh culture media was added, and cells were incubated at 37°C, 5% CO~2~. In some cases, culture media was supplemented with 0.25 mM itaconic acid.

Bacterial cultures {#s10}
------------------

*Mtb* strain Erdman and its derivatives were cultured at 37°C in 7H9 broth (Sigma) or on 7H11 agar (BD Difco) medium supplemented with 10% oleic acid/albumin/dextrose/catalase, 0.5% glycerol, and 0.05% Tween 80 (broth only). *Listeria monocytogenes* (strain EGD) was grown in a shaking culture in brain--heart infusion broth at 37°C to midlogarithmic growth, washed in PBS, and frozen as glycerol stocks at −80°C.

Generation of *Mtb* mutants {#s11}
---------------------------

*Mtb*-GFP was generated by transforming the *Mtb* strain Erdman with a plasmid (pMV261-kan-GFP) that drives constitutive expression of GFP under the control of the *hsp60* promoter. Cultures were grown in the presence of kanamycin to ensure plasmid retention. Δ*icl1 Mtb* was generated by transducing the *Mtb* strain Erdman with a phage containing homology to nucleotides 556805--557527 and 558797--559447 to replace the endogenous *icl1* gene with a hygromycin resistance cassette. Mutants were selected by culture on hygromycin-containing 7H11 agar. Individual hygromycin-resistant colonies were expanded by inoculation into hygromycin-supplemented 7H9 media. Replacement of the *icl1* gene with the hygromycin resistance cassette was confirmed by Southern blotting of genomic DNA from expanded cultures.

Viral cultures {#s12}
--------------

A/California/04/2009 H1N1 influenza viral stocks were prepared as previously described ([@bib22]).

BAL lavage of IAV infected mice {#s13}
-------------------------------

For analysis of BAL fluid, mice were sacrificed by Avertin overdose, followed by anterior neck dissection and cannulation of the trachea with a 22-G catheter. BAL was performed with three washes of 0.8 ml of sterile Hanks' balanced salt solution. BAL fluid was centrifuged and the cell-free supernatant was collected and stored for viral titer analysis.

Flow cytometry {#s14}
--------------

Mice were perfused with sterile PBS and left lobes of lungs were digested at 37°C with 630 µg/ml collagenase D (Roche) and 75 U/ml DNase I (Sigma). All antibodies were used at a dilution of 1:200. Single cell suspensions were preincubated with Fc Block antibody (BD PharMingen) in PBS + 2% heat-inactivated FBS for 10 min at room temperature before staining. Cells were incubated with antibodies against the following markers: V500 anti-CD45.1 (clone A20), AF700 anti-CD45.2 (clone 104; eBioscience), AF700 anti-CD45 (clone 30 F-11), APC-Cy7 anti-CD11c (clone N418), PE anti-Siglec F (clone E50-2440; BD), PE-Cy7 anti-Ly6G (clone 1A8), PB or Qdot605 anti-Ly6C (clone AL-21/HK1.4; Biolegend/BD), PerCP-Cy5.5 anti-CD11b (clone M1/70), APC anti-CD103 (clone 2E7; eBioscience), PB anti-CD3 (clone 17A2), PE-Cy7, APC anti-CD4 (clone RM4-5), PE-Cy7 anti-CD8 (clone53-6.7), anti-NK1.1 (clone PK136), and APC anti-Nos2 (clone CXNFT; all from eBioscience). Intracellular ROS were stained with MitoSOX red dye (Thermo Fisher). Absolute cell counts were determined using TruCount beads (BD). Cells were stained for 20 min at 4°C, washed, and fixed in 4% paraformaldehyde (Electron Microscopy Sciences) in PBS for 20 min at 4°C. Flow cytometry data were acquired on a cytometer (LSR Fortessa; BD Biosciences) and analyzed using FlowJo software (Tree Star). Gating strategies are depicted in Fig. S2.

Cytokine/chemokine quantification {#s15}
---------------------------------

Lungs were homogenized in 5 ml of PBS supplemented with 0.05% Tween 80. Homogenates were filtered (0.22 µm) twice and analyzed by BioPlex-Pro Mouse Cytokine 23-Plex Immunoassay (Bio-Rad).

Histology and imaging {#s16}
---------------------

Lung samples were fixed in 10% buffered formalin (Thermo Fisher). Gross pathology images were acquired using a Power Shot G9 camera (Canon). For detailed histological analysis, lung lobes were embedded in paraffin, sectioned, and stained with H&E (Pulmonary Morphology Core, Washington University). *Mtb* bacilli were stained with Ziehl-Neelsen stain (Pulmonary Morphology Core). Images were acquired using NanoZoomer 2.0-HT System (Hamamatsu) or an Eclipse E400 camera (Nikon).

RNA-seq {#s17}
-------

BMDMs were harvested at 4 h after *Mtb* infection, and RNA was extracted using TRIZol reagent (Invitrogen). mRNA was extracted with oligo-dT beads (Invitrogen) and cDNA synthesized using custom oligo-dT primer with a barcode and adaptor-linker sequence (CCTACACGACGCTCTTCCGATCT-XXXXXXXX-T15). Samples were pooled based on *Actb* qPCR values, RNA--DNA hybrids degraded with acid-alkali treatment and a second sequencing linker (5′-AGATCGGAAGAGCACACGTCTG-3′) was ligated with T4 ligase (NEB). After SPRI bead cleanup (Agencourt AMPure XP; Beckman Coulter), the mixture was PCR-enriched (12 cycles) and SPRI-purified, yielding final strand-specific RNA-seq libraries. Libraries were sequenced on a HiSeq 2500 (Illumina) using 40 × 10 bp paired-end sequencing. Second read (read-mate) was used for sample demultiplexing. Files obtained from the sequencing center were demultiplexed with fastq-multx tool. Fastq files for each sample were aligned to mm10 genome (Release M8 Gencode; GRCm38.p4) using STAR. Each sample was evaluated according to a variety of both pre- and postalignment quality control measures with Picard tools. Aligned reads were quantified using a quant3p script ([@bib3]) to account for specifics of 3′ sequencing: higher dependency on good 3′ annotation and lower level of sequence specificity close to 3′ end. Actual read counts were performed by HTSeq with enriched genome annotation and alignment with fixed multimapper flags. DESeq2 was used for analysis of differential gene expression. Preranked GSEA analysis was used to identify pathway enrichments in hallmark and canonical pathways.

Quantification and statistical analysis {#s18}
---------------------------------------

All data are from at least two independent biological experiments with multiple mice in each group. No blinding was performed during animal experiments. Statistical differences were calculated using Prism 7 (GraphPad) using log-rank Mantel-Cox tests (survival), unpaired two-tailed Mann-Whitney tests (to compare two groups with nonparametric data distribution), and one-way ANOVA with Tukey's multiple comparisons tests (to compare more than two groups with parametric data distribution). Differences with a p-value of \<0.05 were defined as statistically significant.

Data and software availability {#s19}
------------------------------

RNA-seq data are available in the Gene Expression Omnibus repository under reference series number GSE98458.

Online supplemental materials {#s20}
-----------------------------

Further details including generation of *Mtb* mutants, protocols for bacterial cultures, viral cultures, BAL lavage, flow cytometry, chemokine/cytokine quantification, histology, imaging, RNA-seq, quantification, and statistical analysis can be found in the online supplemental methods. Fig. S1 shows that *Irg1^−/−^* mice are susceptible to *ΔIcl1 Mtb*, and infection of WT-*Mtb* or *Mtb*-GFP in WT and *Irg1^−/−^* mice and BMDM. Fig. S2 defines cellular infiltrates in the lungs of WT and *Irg1^−/−^* mice after *Mtb* infection and depletion of neutrophils in the lung. Fig. S3 shows that radiosensitive hematopoietic cells promote Irg1-mediated responses against *Mtb* and assessment of *Irg1* exon 4 deletion in conditional gene-targeted mice.
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